Literature DB >> 30578056

Time-dose response of oxygen delivery during cardiopulmonary bypass predicts acute kidney injury.

Hiroshi Mukaida1, Satoshi Matsushita2, Kenji Kuwaki3, Takahiro Inotani4, Yuki Minami4, Akira Saigusa4, Atsushi Amano3.   

Abstract

OBJECTIVE: Previous studies have reported that nadir oxygen delivery during cardiopulmonary bypass is associated with the occurrence of postoperative acute kidney injury (AKI). However, these measurements only considered the bottom point of the oxygen delivery (DO2) but did not consider the duration of DO2. We aimed to examine whether the time-dose response of DO2 during cardiopulmonary bypass can be used to estimate the risk for postoperative AKI.
METHODS: We evaluated 112 patients who underwent cardiac surgeries with cardiopulmonary bypass. We analyzed the perfusion parameters recorded every 20 seconds. To obtain time-dose response of DO2 index (DO2i), the area under the curve was calculated as below the 300 mL/min/m2 threshold, which accounts for depth and duration of cumulative oxygen debt. In addition, the cumulative time below DO2i 300 mL/min/m2 was also calculated. Receiver operating characteristic analysis, univariate regression analysis, and multivariate regression analysis were used to evaluate associations between perioperative variables and postoperative AKI.
RESULTS: Patients who developed AKI had larger area under the curve below the 300 mL/min/m2 threshold (1581 vs 632; P < .01) and cumulative time below DO2i 300 mL/min/m2 (34.7 vs 15.3 minutes; P < .01). Nadir DO2i was not significantly different between the non-AKI and AKI groups (263.4 vs 247.0 mL/min/m2; P = .291).
CONCLUSIONS: The time-dose response of DO2i during cardiopulmonary bypass is a better indicator than nadir DO2i in evaluating AKI risk. Maintaining DO2i levels >300 mL/min/m2 may result in decreased risk for postoperative AKI.
Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute kidney injury; adequate perfusion; cardiopulmonary bypass; goal-directed perfusion; oxygen delivery

Year:  2018        PMID: 30578056     DOI: 10.1016/j.jtcvs.2018.10.148

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Impact of Oxygen Delivery on the Development of Acute Kidney Injury in Patients Undergoing Valve Heart Surgery.

Authors:  Elena Carrasco-Serrano; Pablo Jorge-Monjas; María Fé Muñoz-Moreno; Esther Gómez-Sánchez; Juan Manuel Priede-Vimbela; Miguel Bardají-Carrillo; Héctor Cubero-Gallego; Eduardo Tamayo; Christian Ortega-Loubon
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

2.  Postoperative saline administration following cardiac surgery: impact of high versus low-volume administration on acute kidney injury.

Authors:  Meletios Kanakis; Thomas Martens; Nagarajan Muthialu
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

3.  Cardiopulmonary Bypass Mean Global Oxygen Delivery May Be Associated with Neurocognitive Preservation during Hypothermic Aortic Surgery.

Authors:  Larry Garrison
Journal:  J Extra Corpor Technol       Date:  2020-12

4.  Goal-directed perfusion to reduce acute kidney injury after paediatric cardiac surgery (GDP-AKIp): study protocol for a prospective randomised controlled trial.

Authors:  Yan Zhang; Xiujuan Zhou; Bo Wang; Lijuan Guo; Ronghua Zhou
Journal:  BMJ Open       Date:  2020-12-10       Impact factor: 2.692

5.  Risk factors for postoperative delirium on oxygen delivery-guided perfusion.

Authors:  Hiroshi Mukaida; Satoshi Matsushita; Yuki Minami; Go Sato; Masato Usuba; Rinako Kondo; Tohru Asai; Atsushi Amano
Journal:  J Cardiothorac Surg       Date:  2022-08-20       Impact factor: 1.522

6.  Intraoperative Oxygen Delivery and Acute Kidney Injury after Liver Transplantation.

Authors:  Won Ho Kim; Ho-Jin Lee; Hee-Chul Yoon; Kook Hyun Lee; Kyung-Suk Suh
Journal:  J Clin Med       Date:  2020-02-19       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.